[go: up one dir, main page]

MX2009010148A - Peptidos ciclicos de proteinas receptor-asociadas (rap). - Google Patents

Peptidos ciclicos de proteinas receptor-asociadas (rap).

Info

Publication number
MX2009010148A
MX2009010148A MX2009010148A MX2009010148A MX2009010148A MX 2009010148 A MX2009010148 A MX 2009010148A MX 2009010148 A MX2009010148 A MX 2009010148A MX 2009010148 A MX2009010148 A MX 2009010148A MX 2009010148 A MX2009010148 A MX 2009010148A
Authority
MX
Mexico
Prior art keywords
rap
receptor
associated protein
peptides
cyclic
Prior art date
Application number
MX2009010148A
Other languages
English (en)
Inventor
Christopher M Starr
Todd C Zankel
Original Assignee
Raptor Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raptor Pharmaceutical Inc filed Critical Raptor Pharmaceutical Inc
Publication of MX2009010148A publication Critical patent/MX2009010148A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se relaciona en general con variantes receptor selectivas de la proteína receptora asociada (RAP) de lipoproteínas de baja densidad y las composiciones de la misma, los métodos para generar estas variantes y los métodos para utilizar estas composiciones de las variantes de la RAP receptor-selectiva para fines terapéuticos.
MX2009010148A 2007-03-21 2008-03-21 Peptidos ciclicos de proteinas receptor-asociadas (rap). MX2009010148A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91923807P 2007-03-21 2007-03-21
PCT/US2008/057863 WO2008116171A1 (en) 2007-03-21 2008-03-21 Cyclic receptor-associated protein (rap) peptides

Publications (1)

Publication Number Publication Date
MX2009010148A true MX2009010148A (es) 2009-12-01

Family

ID=39591450

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010148A MX2009010148A (es) 2007-03-21 2008-03-21 Peptidos ciclicos de proteinas receptor-asociadas (rap).

Country Status (10)

Country Link
US (1) US8440629B2 (es)
EP (1) EP2132224B1 (es)
JP (1) JP2010524849A (es)
KR (2) KR20100015786A (es)
CN (1) CN101861334A (es)
AT (1) ATE539089T1 (es)
BR (1) BRPI0809234A2 (es)
CA (1) CA2681522A1 (es)
MX (1) MX2009010148A (es)
WO (1) WO2008116171A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1583562E (pt) 2003-01-06 2011-09-19 Angiochem Inc Angiopep-1, compostos relacionados, e suas utilizações
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
PT2279008T (pt) 2008-04-18 2019-05-20 Angiochem Inc Composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e utilização
US8129341B2 (en) * 2008-08-25 2012-03-06 New York University Methods for treating diabetic wounds
CN102245636A (zh) 2008-10-15 2011-11-16 安吉奥开米公司 用于药物递送的依托泊苷和多柔比星结合物
CN102245642A (zh) 2008-10-15 2011-11-16 安吉奥开米公司 Glp-1激动剂的结合物及其用途
BRPI0922689A2 (pt) 2008-12-05 2018-11-06 Angiochem Inc. conjugados de neurotensina ou análogos de neurotensina e usos dos mesmos
CN102300987A (zh) 2008-12-17 2011-12-28 安吉奥开米公司 膜型-1基质金属蛋白抑制剂及其用途
EP2416763A4 (en) * 2009-04-06 2015-05-06 Mayo Foundation PROCESS AND MATERIALS FOR THE RELEASE OF MOLECULES
ES2729261T3 (es) 2009-04-20 2019-10-31 Angiochem Inc Tratamiento del cáncer de ovario utilizando un agente anticancerígeno conjugado con un análogo de Angiopep-2
JP5932642B2 (ja) 2009-07-02 2016-06-08 アンジオケム インコーポレーテッド 多量体ペプチドコンジュゲートおよびその使用
JP6170675B2 (ja) * 2010-01-28 2017-07-26 ラプトール ファーマシューティカルズ インコーポレイテッド 受容体関連タンパク質（ｒａｐ）ペプチド−フコシダーゼ阻害薬複合体による肝障害処置のための方法
US9254310B2 (en) 2010-06-17 2016-02-09 New York University Therapeutic and cosmetic uses and applications of calreticulin
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
GB201220474D0 (en) * 2012-11-14 2012-12-26 Sagetis Biotech Sl Polypeptides
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
EP3259280A4 (en) * 2015-02-20 2018-07-18 The Regents of The University of California Methods and compositions for treating glaucoma
CN107921143B (zh) 2015-06-15 2021-11-19 安吉奥开米公司 用于治疗软脑膜癌病的方法
CN109422801B (zh) * 2017-08-31 2022-07-08 复旦大学 多功能靶向多肽rap及其在制备肿瘤靶向递送系统中的用途
CN112040970A (zh) * 2017-11-29 2020-12-04 得克萨斯大学体系董事会 用于癌症疗法的组合物和方法
CN113508175B (zh) * 2018-12-27 2025-08-19 生物阿非尼提科技公司 用于治疗癌症的组合物和方法
US12305171B2 (en) 2018-12-27 2025-05-20 Bioaffinity Technologies, Inc. Compositions and methods for treating cancer
US11572394B2 (en) * 2020-02-16 2023-02-07 Pasteur Institute Of Iran Peptides for targeting LRP6-overexpressed cells
EP3954393A1 (en) 2020-08-13 2022-02-16 Bioasis Technologies Inc. Combination therapies for delivery across the blood brain barrier
CN116286380A (zh) * 2021-12-21 2023-06-23 暨南大学 环五肽类化合物及其在α-糖苷酶抑制剂类降糖药物或预防保健品中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
IT1122765B (it) * 1978-11-06 1986-04-23 Srm Hydromekanik Ab Frizione a dischi multipli
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US5186941A (en) 1983-05-06 1993-02-16 Vestar, Inc. Vesicle formulation for the controlled release of therapeutic agents
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US6238908B1 (en) 1995-06-07 2001-05-29 Aastrom Biosciences, Inc. Apparatus and method for maintaining and growth biological cells
CA2242991C (en) 1996-01-16 2007-07-24 University Technology Corporation Use of antioxidant agents to treat cholestatic liver disease
TW492882B (en) 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US6585971B1 (en) 1999-11-12 2003-07-01 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof
US6426208B1 (en) 1999-11-12 2002-07-30 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US6569661B1 (en) 1999-11-12 2003-05-27 Biomarin Pharmaceutical Inc. Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
US6596762B2 (en) 2001-05-17 2003-07-22 The Regents Of The University Of Colorado Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis
US7485314B2 (en) 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
EP1638605B1 (en) 2003-06-20 2014-01-08 Raptor Pharmaceutical, Inc. Delivery of therapeutic compounds to the brain and other tissues
WO2006138343A2 (en) * 2005-06-14 2006-12-28 Raptor Pharmaceutical Inc. Compositions comprising receptor - associated protein (rap) variants specific for lrp2 and uses thereof
WO2008036682A2 (en) * 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates

Also Published As

Publication number Publication date
BRPI0809234A2 (pt) 2014-09-02
CA2681522A1 (en) 2008-09-25
EP2132224A1 (en) 2009-12-16
KR20100015786A (ko) 2010-02-12
HK1139162A1 (en) 2010-09-10
KR20150104584A (ko) 2015-09-15
KR101801454B1 (ko) 2017-11-24
US8440629B2 (en) 2013-05-14
WO2008116171A1 (en) 2008-09-25
CN101861334A (zh) 2010-10-13
US20100210517A1 (en) 2010-08-19
EP2132224B1 (en) 2011-12-28
JP2010524849A (ja) 2010-07-22
ATE539089T1 (de) 2012-01-15

Similar Documents

Publication Publication Date Title
MX2009010148A (es) Peptidos ciclicos de proteinas receptor-asociadas (rap).
WO2007035716A3 (en) Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
WO2010034032A3 (en) Methods for preparing purified polypeptide compositions
PH12017500866A1 (en) Targeted xten conjugate compositions and methods of making same
WO2006138343A3 (en) Compositions comprising receptor - associated protein (rap) variants specific for lrp2 and uses thereof
WO2009035540A3 (en) Analogues of exendin-4 and exendin-3
PH12019500644A1 (en) Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
MX2010008206A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.
MX2012001139A (es) Metodos para el tratamiento del dolor.
MY158325A (en) Multitype peptide compositions and methods for treatment or prevention of human papillpmavirus infection
MA32936B1 (fr) Polypeptides de recepteur stabilises et leurs utilisations
PH12018502538A1 (en) Antibodies to alpha-synuclein and uses thereof
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
UA107329C2 (uk) Туберкульозний білок rv2386c, композиція, що його містить, та застосування
PH12013500481A1 (en) Estrogen receptor modulators and uses thereof
PH12012502419A1 (en) Estrogen receptor modulators and uses thereof
EA201270528A1 (ru) Композиции цитокинов семейства il-17 и их применение
WO2010003268A3 (en) Methods and compositions for enhanced delivery of macromolecules
MX2010010457A (es) Vectores recombinantes de rinovirus.
EA201170659A1 (ru) Антитела к рецептору ii tgf-вета
MX2010002769A (es) Preparacion recombinante de fracciones de bromelaina seleccionadas.
EA201070725A1 (ru) Бис-пиридилпиридоны как антагонисты рецептора 1 меланинконцентрирующего гормона

Legal Events

Date Code Title Description
FG Grant or registration